Combining drugs and extending treatment - a PFS end point is not sufficient

被引：20

作者：

Gyawali, Bishal ^{[1
]}

Prasad, Vinay ^{[2
,3
,4
]}

机构：

[1] Kings Coll London, Inst Canc Policy, London SE1 9RT, England

[2] OHSU, Div Hematol Oncol, Knight Canc Inst, 3181 South West Sam Jackson Pk Rd, Portland, OR 97239 USA

[3] OSHU, Dept Publ Hlth & Prevent Med, 3181 South West Sam Jackson Pk Rd, Portland, OR 97239 USA

[4] OSHU, Ctr Hlth Care Eth, 3181 South West Sam Jackson Pk Rd, Portland, OR 97239 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 09期

关键词：

BRENTUXIMAB VEDOTIN; CANCER; TRIAL; CONSOLIDATION; SURVIVAL; EFFICACY; LYMPHOMA; ONCOLOGY; THERAPY; RELAPSE;

D O I：

10.1038/nrclinonc.2017.72

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In studies investigating the combination of two or more anticancer drugs that are already approved for independent use, or 'maintenance' regimens, the use of progression-free survival as the end point for approval is inadequate; sequential treatment with the same agents or existing salvage therapies, respectively, might provide an equivalent survival benefit, with lower toxicity, cost, and treatment burden, therefore, the use of an overall survival end point is essential to justify such interventions.

引用

页码：521 / 522

页数：2

共 8 条

[1] Progression-Free Survival: Meaningful or Simply Measurable? [J].

Booth, Christopher M. ;

Eisenhauer, Elizabeth A. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1030-1033

[2] Routine Cancer Antigen 125 Surveillance-The Fatal Attraction of Testing [J].

Goodwin, James S. .

JAMA ONCOLOGY, 2016, 2 (11) :1412-+

[3] Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study [J].

Hanna, NH ;

Sandler, AB ;

Loehrer, PJ ;

Ansari, R ;

Jung, SH ;

Lane, K ;

Einhorn, LH .

ANNALS OF ONCOLOGY, 2002, 13 (01) :95-102

[4]

Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]

[5] Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs [J].

Mailankody, Sham ;

Prasad, Vinay .

JAMA ONCOLOGY, 2015, 1 (04) :539-540

[6] Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Moskowitz, Craig H. ;

Nademanee, Auayporn ;

Masszi, Tamas ;

Agura, Edward ;

Holowiecki, Jerzy ;

Abidi, Muneer H. ;

Chen, Andy I. ;

Stiff, Patrick ;

Gianni, Alessandro M. ;

Carella, Angelo ;

Osmanov, Dzhelil ;

Bachanova, Veronika ;

Sweetenham, John ;

Sureda, Anna ;

Huebner, Dirk ;

Sievers, Eric L. ;

Chi, Andy ;

Larsen, Emily K. ;

Hunder, Naomi N. ;

Walewski, Jan .

LANCET, 2015, 385 (9980) :1853-1862

[7] The Strength of Association Between Surrogate End Points and Survival in Oncology A Systematic Review of Trial-Level Meta-analyses [J].

Prasad, Vinay ;

Kim, Chul ;

Burotto, Mauricio ;

Vandross, Andrae .

JAMA INTERNAL MEDICINE, 2015, 175 (08) :1389-1398

[8] Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse [J].

Sweetenham, John W. ;

Walewski, Jan ;

Nadamanee, Auayporn ;

Masszi, Tamas ;

Agura, Edward ;

Holowiecki, Jerzy ;

Abidi, Muneer H. ;

Chen, Andy L. ;

Stiff, Pat ;

Viviani, Simonetta ;

Carella, Angelo ;

Osmanov, Dzhelil ;

Bachanova, Veronika ;

Sureda, Anna ;

Huebner, Dirk ;

Larsen, Emily K. ;

Hunder, Naomi N. ;

Moskowitz, Craig H. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) :S36-S37

← 1 →